Current Treatments and Controversies in Neuroendocrine Neoplasia

Pavel, Marianne; Bolduan, Felix; Wiedenmann, Bertram; Perren, Aurel (10 November 2022). Current Treatments and Controversies in Neuroendocrine Neoplasia. ASCO Daily News ASCO American Society of Clinical Oncology

Full text not available from this repository. (Request a copy)

Although advances in understanding the mutational and transcriptomic landscape of neuroendocrine tumors (NETs) have been made, a dearth of targetable biomarkers and unclear therapeutic pathways remain.
Historically, somatostatin analogs, radioligand therapy, immunosuppressants, tyrosine kinase inhibitors, and chemotherapy have been prescribed to patients with NETs, with varying results; emerging therapeutic options include immunotherapies and chimeric antigen receptor T-cell therapies.

Although the mutational and transcriptomic landscape of neuroendocrine tumors (NETs) has been increasingly elucidated, direct oncogenic and targetable mutations such as RET mutations in medullary thyroid carcinomas remain absent, and no response predictions to treatments are available. Somatostatin receptor (SSTR) expression is, however, a key feature of NETs for therapy selection.

Item Type:	Newspaper or Magazine Article
Division/Institute:	04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology
UniBE Contributor:	Perren, Aurel
Subjects:	600 Technology > 610 Medicine & health
Publisher:	ASCO American Society of Clinical Oncology
Language:	English
Submitter:	Sandra Wittwer
Date Deposited:	15 Feb 2023 12:21
Last Modified:	15 Feb 2023 23:28
URI:	https://boris.unibe.ch/id/eprint/178717